623143-35-1

Usage

Uses

Used in Pharmaceutical Research:
Benzenemethanamine, alpha-ethyl-3-methoxy-, (alphaS)(9CI) could be used as a research compound for studying the effects of psychoactive substances on the central nervous system. This may aid in understanding the mechanisms of action and potential therapeutic applications, while also informing the development of treatments for addiction and mental health disorders.
Used in Forensic Toxicology:
In the field of forensic toxicology, Benzenemethanamine, alpha-ethyl-3-methoxy-, (alphaS)(9CI) may be utilized as a reference substance for the identification and analysis of illicit drugs in biological samples. This helps in the investigation of drug-related crimes and the assessment of drug impairment in cases such as driving under the influence.
Used in Neuropharmacology:
As a compound with known stimulant and hallucinogenic effects, Benzenemethanamine, alpha-ethyl-3-methoxy-, (alphaS)(9CI) may be employed in neuropharmacological research to explore the interactions between psychoactive substances and neurotransmitter systems. This can contribute to the advancement of knowledge on the neurochemical basis of mood, perception, and cognition.

Upstream product

• 1527-89-5 3-methoxybenzonitrile 
• 925-90-6 ethylmagnesium bromide 
• 591-31-1 3-methoxy-benzaldehyde 

Relevant academic research and scientific papers

Methods and compositions for treating amyloid-related diseases

Methods, compounds, pharmaceutical compositions and kits are described for treating or preventing amyloid-related disease.

HELIX 12 DIRECTED STEROIDAL PHARMACEUTICAL PRODUCTS

Compounds having the structure or their salts: are used to treat or reduce le likelihood of acquiring androgen-dependent diseases, such as prostate cancer, benign prostatic hyperplasia, polycystic ovarian syndrome, acne, hirsutism, seborrhea, androgenic alopecia and male baldness. They can be formulated together with pharmaceutically acceptable diluent or carrier or otherwise made into any pharmaceutical dosage form. Some of these compounds having tissue-specific antiandrogenic activity and tissue-specific androgenic activity can be used to treat or reduce the risk of developing diseases related to loss of androgenic stimulation. Combinations with other active pharmaceutical agents are also disclosed.

THIADIAZOLEDIOXIDES AND THIADIAZOLEOXIDES AS CXC- AND CC-CHEMOKINE RECEPTOR LIGANDS

Disclosed are novel compounds of the formula (IA) and the pharmaceutically acceptable salts and solvates thereof. Examples of groups comprising Substituent A include heteroaryl, aryl, heterocycloalkyl, cycloalkyl, aryl, alkynyl, alkenyl, aminoalkyl, alkyl or amino. Examples of groups comprising Substituent B include aryl and heteroaryl. Also disclosed is a method of treating a chemokine mediated diseases, such as, cancer, angiogenisis, angiogenic ocular diseases, pulmonary diseases, multiple sclerosis, rheumatoid arthritis, osteoarthritis, stroke and cardiac reperfusion injury, acute pain, acute and chronic inflammatory pain, and neuropathic pain using a compound of formula (IA).

3,4-Di-substituted cyclobutene-1,2-diones as CXC-chemokine receptor ligands

There are disclosed compounds of the formula or a pharmaceutically acceptable salt or solvate thereof which are useful for the treatment of chemokine-mediated diseases such as acute and chronic inflammatory disorders and cancer.

3,4-Di-substituted cyclobutene-1,2-diones as CXC-chemokine receptor ligands

There are disclosed compounds of the formula or a pharmaceutically acceptable salt or solvate thereof which are useful for the treatment of chemokine-mediated diseases such as acute and chronic inflammatory disorders and cancer.